{"id":"W2019837162","doi":"10.1007/s10637-014-0169-3","title":"A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Bevacizumab; Mucositis; Discontinuation; Internal medicine; Interim analysis; Gastroenterology; Sorafenib; Hepatocellular carcinoma; Phases of clinical research; Clinical endpoint; Progression-free survival; Surgery; Toxicity; Clinical trial; Chemotherapy; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001417569,0.001215229,0.00264361,0.0004256376,0.0003734271,0.0008962076,0.0005316189,0.0008900889,0.003023944],"category_scores_gemma":[0.00113053,0.0005093274,0.001464267,0.0004767956,0.0008599869,0.00110529,0.0004197537,0.003015293,0.0006211151],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008926202,"about_ca_system_score_gemma":0.001308423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001009964,"about_ca_topic_score_gemma":0.002691306,"domain_scores_codex":[0.9995666,0.0002336165,0.00002428835,0.00007042418,0.0000272027,0.00007783235],"domain_scores_gemma":[0.9993435,0.0001326666,0.00009595168,0.00005007973,0.00003364054,0.0003442792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9023845,0.01468624,0.004077192,0.0005255237,0.001630043,0.0001463754,0.0001404771,0.001904373,0.01155699,0.0002071176,0.002466123,0.060275],"study_design_scores_gemma":[0.8214917,0.1671256,0.006677737,0.00002659758,0.0006030002,0.0001383601,0.00006488525,0.001083495,0.001025613,0.00017754,0.001561757,0.00002374408],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933544,0.002571007,0.0003296571,0.0009857598,0.0002455466,0.0007153327,0.0004340639,0.00006533515,0.00129888],"genre_scores_gemma":[0.9922723,0.001939854,0.001024455,0.0007943049,0.0002330902,0.0009398868,0.001358745,0.00002185596,0.001415512],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003023944,"threshold_uncertainty_score":0.0101161,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0276207536430723,"score_gpt":0.2415496491141181,"score_spread":0.2139288954710458,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}